**1. Introduction**

Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are two chronic inflammatory autoimmune diseases of the bile ducts, which could culminate in biliary cirrhosis. Very few treatment options were available for decades, but in the past years many new targets and therapies were investigated, and clinical trials were performed.

The aim of this review is to provide an update on new targets and novel therapies that may change the management of these diseases in the near future.
